Literature DB >> 23417506

Distinguishing hazards and harms, adverse drug effects and adverse drug reactions : implications for drug development, clinical trials, pharmacovigilance, biomarkers, and monitoring.

Jeffrey K Aronson1.   

Abstract

The terms 'adverse drug effects' and 'adverse drug reactions' are commonly used interchangeably, but they have different implications. Adverse drug reactions arise when a compound (e.g. a drug or metabolite, a contaminant or adulterant) is distributed in the same place as a body tissue (e.g. a receptor, enzyme, or ion channel), and the encounter results in an adverse effect (a physiological or pathological change), which results in a clinically appreciable adverse reaction. Both the adverse effect and the adverse reaction have manifestations by which they can be recognized: adverse effects are usually detected by laboratory tests (e.g. biochemical, haematological, immunological, radiological, pathological) or by clinical investigations (e.g. endoscopy, cardiac catheterization), and adverse reactions by their clinical manifestations (symptoms and/or signs). This distinction suggests five scenarios: (i) adverse reactions can result directly from adverse effects; (ii) adverse effects may not lead to appreciable adverse reactions; (iii) adverse reactions can occur without preceding adverse effects; (iv) adverse effects and reactions may be dissociated; and (v) adverse effects and reactions can together constitute syndromes. Defining an adverse drug reaction as "an appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal product" suggests a definition of an adverse drug effect: "a potentially harmful effect resulting from an intervention related to the use of a medicinal product, which constitutes a hazard and may or may not be associated with a clinically appreciable adverse reaction and/or an abnormal laboratory test or clinical investigation, as a marker of an adverse reaction."

Mesh:

Substances:

Year:  2013        PMID: 23417506     DOI: 10.1007/s40264-013-0019-9

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  20 in total

Review 1.  Comparative safety of the different macrolides.

Authors:  E Rubinstein
Journal:  Int J Antimicrob Agents       Date:  2001       Impact factor: 5.283

Review 2.  Paradoxical and bidirectional drug effects.

Authors:  Silas W Smith; Manfred Hauben; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2012-03-01       Impact factor: 5.606

3.  Hazards, risks and reality.

Authors:  R E Ferner
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

Review 4.  Clarification of terminology in drug safety.

Authors:  Jeffrey K Aronson; Robin E Ferner
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  Multiplicity of medication safety terms, definitions and functional meanings: when is enough enough?

Authors:  K H Yu; R L Nation; M J Dooley
Journal:  Qual Saf Health Care       Date:  2005-10

6.  EIDOS: a mechanistic classification of adverse drug effects.

Authors:  Robin E Ferner; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

7.  Surrogate endpoints in clinical trials: cardiovascular diseases.

Authors:  J Wittes; E Lakatos; J Probstfield
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

8.  Autoimmune haemolytic anaemia associated with alpha-methyldopa therapy.

Authors:  S M Worlledge; K C Carstairs; J V Dacie
Journal:  Lancet       Date:  1966-07-16       Impact factor: 79.321

9.  Subchronic inhalation toxicity of ethylbenzene in mice, rats, and rabbits.

Authors:  S T Cragg; E A Clarke; I W Daly; R R Miller; J B Terrill; R E Ouellette
Journal:  Fundam Appl Toxicol       Date:  1989-10

Review 10.  Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring.

Authors:  Patrick Garnero
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

View more
  14 in total

1.  Multiplicity of Terms Related to Patient Safety: A Hindrance to Progress.

Authors:  Marc Perreault
Journal:  Can J Hosp Pharm       Date:  2015 Sep-Oct

2.  [Not Available].

Authors:  Marc Perreault
Journal:  Can J Hosp Pharm       Date:  2015 Sep-Oct

3.  Predicting Adverse Drug Effects from Literature- and Database-Mined Assertions.

Authors:  Mary K La; Alexander Sedykh; Denis Fourches; Eugene Muratov; Alexander Tropsha
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

4.  Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis.

Authors:  Irma Convertino; Stefano Salvadori; Alessandro Pecori; Maria Teresa Galiulo; Sara Ferraro; Maria Parrilli; Tiberio Corona; Giuseppe Turchetti; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

5.  Quality of pharmacotherapy in old age: focus on lists of Potentially Inappropriate Medications (PIMs) : Consensus statements from the European Science Foundation exploratory workshop.

Authors:  Majda Azermai; Robert R Vander Stichele; Monique M Elseviers
Journal:  Eur J Clin Pharmacol       Date:  2016-04-11       Impact factor: 2.953

Review 6.  Categorization and association analysis of risk factors for adverse drug events.

Authors:  Lina Zhou; Anamika Paul Rupa
Journal:  Eur J Clin Pharmacol       Date:  2017-12-08       Impact factor: 2.953

7.  Artificial Intelligence in Pharmacovigilance: An Introduction to Terms, Concepts, Applications, and Limitations.

Authors:  Jeffrey K Aronson
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.606

8.  Adverse events in people taking macrolide antibiotics versus placebo for any indication.

Authors:  Malene Plejdrup Hansen; Anna M Scott; Amanda McCullough; Sarah Thorning; Jeffrey K Aronson; Elaine M Beller; Paul P Glasziou; Tammy C Hoffmann; Justin Clark; Chris B Del Mar
Journal:  Cochrane Database Syst Rev       Date:  2019-01-18

9.  Effects of anticoagulation therapy with vitamin K antagonists on hospitalizations and emergency room accesses in Grosseto (Italy).

Authors:  F NISTICò; G Troiano; N Nante; S Dei; P Piacentini
Journal:  J Prev Med Hyg       Date:  2018-03-30

10.  Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.

Authors:  G M Goodwin; P M Haddad; I N Ferrier; J K Aronson; Trh Barnes; A Cipriani; D R Coghill; S Fazel; J R Geddes; H Grunze; E A Holmes; O Howes; S Hudson; N Hunt; I Jones; I C Macmillan; H McAllister-Williams; D R Miklowitz; R Morriss; M Munafò; C Paton; B J Saharkian; Kea Saunders; Jma Sinclair; D Taylor; E Vieta; A H Young
Journal:  J Psychopharmacol       Date:  2016-03-15       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.